Drug intelligence / Profile preview

bevacizumab + ranibizumab + tenecteplase

Development stage: Preclinical
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravitreal

Overview

A combination therapy consisting of bevacizumab or ranibizumab (anti-VEGF agents) with tenecteplase (a tissue plasminogen activator) and gas, used primarily for the treatment of submacular hemorrhage (SMH) secondary to neovascular age-related macular degeneration (nAMD). The therapeutic principle is based on three synergistic effects: the non-toxic and highly penetrating ability of tenecteplase to lyse blood clots, the mechanical displacement of submacular liquefied blood through gas bubbles, and the treatment of underlying choroidal neovascularization with anti-VEGF agents.

Targets

VEGFA (Vascular endothelial growth factor A)PLG (Plasminogen)

Beyond the preview

Go deeper on bevacizumab + ranibizumab + tenecteplase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bevacizumab + ranibizumab + tenecteplase.

Explore the full profile